Order Article Reprints

Peisen F, Gerken A, Hering A, Dahm I, Nikolaou K, Gatidis S, Eigentler TK, Amaral T, Moltz JH, Othman AE. Can Whole-Body Baseline CT Radiomics Add Information to the Prediction of Best Response, Progression-Free Survival, and Overall Survival of Stage IV Melanoma Patients Receiving First-Line Targeted Therapy: A Retrospective Register Study. Diagnostics. 2023; 13(20):3210. https://doi.org/10.3390/diagnostics13203210

Peisen, Felix, Annika Gerken, Alessa Hering, Isabel Dahm, Konstantin Nikolaou, Sergios Gatidis, Thomas K. Eigentler, Teresa Amaral, Jan H. Moltz, and Ahmed E. Othman. 2023. "Can Whole-Body Baseline CT Radiomics Add Information to the Prediction of Best Response, Progression-Free Survival, and Overall Survival of Stage IV Melanoma Patients Receiving First-Line Targeted Therapy: A Retrospective Register Study" Diagnostics 13, no. 20: 3210. https://doi.org/10.3390/diagnostics13203210

Peisen, F., Gerken, A., Hering, A., Dahm, I., Nikolaou, K., Gatidis, S., Eigentler, T. K., Amaral, T., Moltz, J. H., & Othman, A. E. (2023). Can Whole-Body Baseline CT Radiomics Add Information to the Prediction of Best Response, Progression-Free Survival, and Overall Survival of Stage IV Melanoma Patients Receiving First-Line Targeted Therapy: A Retrospective Register Study. Diagnostics, 13(20), 3210. https://doi.org/10.3390/diagnostics13203210